#WODC USA Session preview – Addressing the Why Behind Treatment Nonadherence: Leveraging Health Psychology to Design Effective Interventions in Rare Disease
Who is it for?
Adherence is an issue that is relevant for many stakeholders within pharma. This workshop is particularly suitable for brand/product director/managers, patient engagement/insights specialists, patient adherence center of excellence leads, medical science liaisons and internal market research/analytic teams.
What is the problem pharma faces that your approach in nonadherence can help resolve?
The challenge of nonadherence has existed for as long as prescribed treatments have existed. Nonadherence does not discriminate by illness or treatment, and is a concern for all healthcare stakeholders, including those with a focus on rare disease. Successful efforts to address the challenge have been scarce, but a lot has been learned through previous efforts. This workshop will address 2 necessary elements to any successful adherence program:
- What does an effective intervention look like for a specific patient?
- How do we scale this across markets and conditions?
What are the benefits of your approach for improving nonadherence?
The application of health psychology allows us to identify and address the unhelpful beliefs that drive individual health-related behaviors, including nonadherence to prescribed treatment. This approach enables us to create evidence-based support programs for sustained improvements in adherence and improved self-management.
What are the benefits of attending your workshop?
By attending this course, you will learn how the application of health psychology can drive a more effective way of understanding beliefs that drive behaviors in a target population, and how to leverage those insights to develop a more relevant and effective set of interventions.
What are the topics you’re going to cover?
This Workshop will balance theory with practice, and cover the following topics:
- Conceptualizing treatment nonadherence – what is it, how common is it, why is it a problem, and how do we measure it?
- Reasons for treatment nonadherence – applying psychological models to understand drivers behind nonadherent behaviors
- Developing interventions to enhance adherence – what are the key characteristics of successful interventions, and how can pharma apply these to patients living with rare disease
- Deploying adherence interventions within market and regulatory constraints – key considerations for pharma